Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving FTI Consulting, Inc. and its officers or directors [1]. Financial Performance - FTI Consulting reported first-quarter 2025 revenue of $898.3 million, a year-over-year decline of 3.3%, missing consensus estimates by $8.38 million [3]. - The company reported net income of $61.8 million, down from $80 million in the same period the previous year, attributed to lower revenues and a $25.3 million special charge related to severance and employee-related costs [3]. - Following the financial results announcement, FTI's stock price decreased by $6.60 per share, or 3.92%, closing at $161.91 per share on April 24, 2025 [3].

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Amerant Bancorp Inc. (“Amerant” or the “Company”) (NYSE: AMTB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Amerant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 23, 20 ...

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of GoHealth, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - The U.S. Department of Justice filed a False Claims Act complaint against GoHealth and other health insurance companies, alleging that from 2016 to at least 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments into Medicare Advantage plans [3] - Following the DOJ's lawsuit announcement, GoHealth's stock price dropped by $1.09 per share, a decrease of 10.35%, closing at $9.44 per share on May 1, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Group 1: Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [3] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [3] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [3] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [3]

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Open Lending Corporation. (“Open Lending” or the “Company”) (NASDAQ: LPRO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Open Lending an ...

Group 1 - A class action lawsuit has been filed against Napco Security Technologies, Inc. for alleged securities fraud and unlawful business practices [2][4]. - Investors have until June 24, 2025, to request appointment as Lead Plaintiff if they purchased Napco securities during the Class Period [2]. - Napco reported a significant decline in hardware sales attributed to reduced sales from two major distributors, leading to the withdrawal of its long-term 45% EBITDA margin target [4]. Group 2 - Following the announcement of the financial results, Napco's stock price dropped by $9.77 per share, or 26.62%, closing at $26.93 per share on February 3, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Amerant Bancorp Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - Amerant Bancorp reported GAAP earnings per share of $0.28 for Q1 2025, which was $0.12 below consensus estimates [3]. - The company's loans remained relatively flat quarter over quarter due to increased payoffs and paydowns offsetting new production [3]. - Following the earnings announcement, Amerant's stock price decreased by $2.55, or 13.09%, closing at $16.93 per share on April 24, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving FTI Consulting, Inc. and its officers or directors [1] Financial Performance - FTI Consulting reported first-quarter 2025 revenue of $898.3 million, a year-over-year decline of 3.3%, missing consensus estimates by $8.38 million [3] - The company reported net income of $61.8 million, down from $80 million in the same period last year, attributed to lower revenues and a $25.3 million special charge related to severance and employee-related costs [3] - Following the financial results announcement, FTI's stock price decreased by $6.60 per share, or 3.92%, closing at $161.91 per share on April 24, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Senti Biosciences, Inc. following a significant drop in stock price due to halted clinical trials [1][3]. Group 1: Company Developments - On April 28, 2025, Senti announced the cessation of enrollment in the Investigator Sponsored Trial for its solid tumor product SN301A due to observed dose limiting toxicities [3]. - Following this announcement, Senti's stock price decreased by $1.36 per share, representing a 27.2% decline, closing at $3.64 per share [3]. Group 2: Legal Investigation - Pomerantz LLP is representing investors of Senti and is looking into claims of securities fraud or other unlawful practices by the company and its officers or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action investigation [1].

Core Viewpoint - T-Mobile US, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing first-quarter financial results that led to a significant drop in stock price [1][3]. Financial Performance - T-Mobile reported adding only 495,000 postpaid phone net customers in Q1 2025, which was below the consensus expectation of 506,557 net customers [3]. - Following the earnings announcement, T-Mobile's stock price fell by $29.41 per share, or 11.22%, closing at $232.77 per share on April 25, 2025 [3]. Legal Investigation - Pomerantz LLP is investigating claims on behalf of T-Mobile investors regarding possible securities fraud or other unlawful business practices by the company and its officers or directors [1].